Allia Elena, Tarabra Elena, Volante Marco, Cerrato Milena, Ghigo Ezio, Muccioli Giampiero, Papotti Mauro
Department of Biomedical Sciences and Oncology, University of Turin, Turin, Italy.
J Pathol. 2005 Nov;207(3):336-45. doi: 10.1002/path.1839.
Cortistatin (CST), a novel hormone originally described in the rat, mouse, and human cerebral cortex, displays structural and functional similarities to somatostatin (SRIF). CST binds to all five somatostatin receptors and, differently from SRIF, also binds to MrgX2, which has recently been identified as its specific receptor. Little is known about the distribution of CST and MrgX2 in peripheral non-tumour and neoplastic tissues. The aim of the present study was therefore to determine by immunohistochemistry and mRNA analysis (RT-PCR) the distribution of CST and MrgX2 in 56 human non-tumour and 108 tumour tissues, with special reference to neuroendocrine tissue types. Despite the high level of CST mRNA expression in non-tumour and tumour (both neuroendocrine and non-neuroendocrine) tissues, the presence of immunoreactive CST was confirmed in a subset of gastroenteropancreatic, parathyroid, and pituitary non-tumour cells only, and showed a predominantly focal pattern in most neuroendocrine tumours. Co-localization experiments in the gastroenteropancreatic system demonstrated that the normal CST-producing cells are delta cells, while in the adenohypophysis no preferential co-localization of CST with any of the pituitary hormones was observed. MrgX2 mRNA was variably detected in the hypothalamus, pituitary, thyroid, lung, gastroenteropancreatic tract, testis, and ovary, and was negative in the cerebral cortex, parathyroid, and adrenal, as well as in a variety of tumour types. Conversely, immunolocalization of MrgX2 protein was restricted to neurohypophysis and testis, whilst all tumours analysed were negative. A possible explanation for the discrepancy between RT-PCR and immunohistochemistry is that MrgX2 protein was widely detected in blood vessels, scattered lymphocytes, and gastrointestinal ganglia in both normal and neoplastic samples. The findings demonstrate a selective distribution of CST in normal and neoplastic neuroendocrine tissues, suggesting that CST might have a broader functional role than previously assumed, whereas possible autocrine/paracrine actions via its recently described specific receptor MrgX2 are restricted to selected tissues.
促皮质素释放抑制因子(CST)是最初在大鼠、小鼠和人类大脑皮层中发现的一种新型激素,与生长抑素(SRIF)在结构和功能上具有相似性。CST可与所有五种生长抑素受体结合,与SRIF不同的是,它还能与MrgX2结合,最近已确定MrgX2是其特异性受体。关于CST和MrgX2在周围非肿瘤组织和肿瘤组织中的分布情况,人们了解甚少。因此,本研究的目的是通过免疫组织化学和mRNA分析(逆转录聚合酶链反应,RT-PCR)来确定CST和MrgX2在56例人类非肿瘤组织和108例肿瘤组织中的分布情况,特别关注神经内分泌组织类型。尽管在非肿瘤组织和肿瘤组织(包括神经内分泌组织和非神经内分泌组织)中CST mRNA表达水平较高,但免疫反应性CST仅在胃肠胰、甲状旁腺和垂体的一部分非肿瘤细胞中得到证实,并且在大多数神经内分泌肿瘤中呈主要的局灶性分布模式。胃肠胰系统的共定位实验表明,正常产生CST的细胞是δ细胞,而在腺垂体中未观察到CST与任何一种垂体激素有优先共定位现象。MrgX2 mRNA在下丘脑、垂体、甲状腺、肺、胃肠胰道、睾丸和卵巢中均有不同程度的检测到,而在大脑皮层、甲状旁腺、肾上腺以及多种肿瘤类型中呈阴性。相反,MrgX2蛋白的免疫定位仅限于神经垂体和睾丸,而所有分析的肿瘤均为阴性。RT-PCR和免疫组织化学结果存在差异的一个可能解释是,在正常和肿瘤样本的血管、散在淋巴细胞和胃肠神经节中广泛检测到了MrgX2蛋白。这些发现表明CST在正常和肿瘤神经内分泌组织中存在选择性分布,提示CST可能具有比先前认为的更广泛的功能作用,而通过其最近描述的特异性受体MrgX2可能产生的自分泌/旁分泌作用仅限于特定组织。